Is Merck stock really cheap? Merck & Co., Inc. (NYSE:MRK) is guiding for adjusted EPS between $3.45 and $3.55. At the midpoint, its P/E is 13.5.

The pharmaceutical company said it will discontinue the extension phases of preladenant's Phase III studies and no longer plans to pursue regulatory filings for the drug.

Merck & Co., Inc. (NYSE:MRK) also announced today that it would be buying back additional shares. The company plans to spend $5 billion on almost 100 million shares that Goldman Sachs owns.

Merck & Co., Inc. (NYSE:MRK) Federal Reserve officials seem to be having a running internal debate about the efficacy and future of quantitative easing.

Merck & Co., Inc. (NYSE:MRK) was in 56 hedge funds' portfolio at the end of March. MRK investors should pay attention to a decrease in hedge fund sentiment of late.

Medtronic, Inc. (NYSE:MDT) There's hardly any certainty in the market, but even I have to admit it's become almost comical that the Nasdaq Composite has hit a new high (including intraday highs) in 17 straight sessions while the broad-based S&P 500 ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S.

Emerging markets like China are proving to be a big boon for Merck & Co., Inc. (NYSE:MRK) as evidenced by the region's 6% year over year growth.

Merck & Co., Inc. (NYSE:MRK) has also dropped, falling 1.4% after the FDA expressed concerns about the side effects of the company's suvorexant insomnia drug.

Merck & Co., Inc. (NYSE:MRK) Overweight and have high cholesterol? You may have to pick one to work on at a time, according to data from the lab of John Thyfault, an associate professor of nutrition and exercise physiology at University of Missouri.